Page 8 - Mark Fishman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aditum Bio launches third company, Anteris Bio, in collaboration with TrialSpark - Aditum Bio "spin-out" companies such as Anteris Bio will leverage TrialSpark's clinical development engine to rapidly advance their drug assets through clinical trials. News provided by Share this article Share this article NEW YORK, Dec. 16, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, formally announces a collaboration with Aditum Bio, a San Francisco-based venture firm focused on acquiring and developin...

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. M...